Ocular Hypertension (OHT)Symptoms, Doctors, Treatments, Advances & More
Ocular Hypertension (OHT) Overview
Learn About Ocular Hypertension (OHT)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
The Johns Hopkins Hospital
Dr. Pradeep Ramulu is a glaucoma specialist and the director of the Wilmer Eye Institute glaucoma division. He specializes in caring for both routine and complex glaucomas, including glaucomas requiring repeat operations, glaucoma occurring in the context of corneal or retinal disease and glaucoma occurring in newborns and young children. The Sheila K. West Professor of Ophthalmology at the Wilmer Eye Institute, Dr. Ramulu grew up in suburban Chicago, and became interested in the eye during medical school, during which time he studied the genes and proteins of the eye with Dr. Jeremy Nathans. After pursuing a residency in ophthalmology and fellowship training in glaucoma, he joined Wilmer in 2006. Dr. Ramulu is rated as an Elite provider by MediFind in the treatment of Ocular Hypertension (OHT). His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Cataract, Iridectomy, and Cataract Removal.
The Johns Hopkins Hospital
Dr. Harry A. Quigley is the A. Edward Maumenee Professor of Ophthalmology and developed the Glaucoma Division at the Johns Hopkins Wilmer Eye Institute. He was a founding member of the American Glaucoma Society, serving for 8 years as its Secretary and was elected to 5 year terms as chief executive officer of the Association for Research in Vision and Ophthalmology (ARVO) and editor-in-chief of Investigative Ophthalmology and Visual Science. He has published over 350 peer-reviewed articles, and his reports are the most cited in the ophthalmic literature over the last 30 years (Archives of Ophthalmology, 2007). His research has improved the early diagnosis of glaucoma and has developed instruments and techniques to identify glaucoma damage better. He has participated in pioneering studies of the epidemiology, morbidity and progression rate of glaucoma and other eye disease in American, African, Asian and Hispanic populations, serving as a consultant to the World Health Organization. In the laboratory, he has demonstrated successful gene therapy to protect retinal ganglion cells from experimental glaucoma and developed glaucoma models in monkeys, rats and mice. Dr. Quigley is rated as an Elite provider by MediFind in the treatment of Ocular Hypertension (OHT). His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Trabeculectomy, and Iridectomy.
Glaucoma Associates Of Texas - Dallas
Davinder Grover is an Ophthalmologist in Dallas, Texas. Dr. Grover is rated as an Elite provider by MediFind in the treatment of Ocular Hypertension (OHT). His top areas of expertise are Glaucoma, Pigment-Dispersion Syndrome, Ocular Hypertension (OHT), Trabeculectomy, and Iridectomy.
Summary: Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
Summary: The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.


